Stevanato partners with CEPI for 2 billion vaccine vials

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Nordroden)
(Image: Getty/Nordroden)

Related tags: CEPI, Stevanato Group, Coronavirus, COVID-19, Vaccine, Vials

CEPI signs agreement for supply of glass vials to speed up COVID-19 vaccine development timeline.

The partnership between Stevanato Group and the Coalition for Epidemic Preparedness (CEPI) sees the former agree to supply 100 million Type 1 borosilicate glass vials, which can hold up to two billion doses of vaccine.

In addition to capacity, CEPI will be provided ‘fast track’ access to Stevanato’s glass vial forming lines.

The CEO of Stevanato, Franco Stevanato, stated that since the beginning of the pandemic outbreak, the company has been working on increasing global capacity to support the industry’s efforts to scale vaccines against the novel coronavirus.

For CEPI, the move allows it to secure services in parallel to the work it is carrying out to support the clinical development of COVID-19 vaccines. The organization plans to be part of the process that sees the world receive a commercially available vaccine in the next 12 to 18 months.

As part of this ambition, CEPI is playing a role in ensuring that AstraZeneca is able to produce two billion doses​ of its vaccine candidate by 2021.

The organization also provided record investment to Novavax​, allowing the company to purchase additional capacity to produce its potential COVID-19 vaccine.

The move by CEPI echoes a similar push by the US government to invest in syringe and vial production​ to ensure any successfully developed vaccine has the materials ready to be delivered once approved.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more